Nizatidine is a histamine H2 receptor antagonist that inhibits stomach acid production, and is commonly used in the treatment of peptic ulcer disease and gastroesophageal reflux disease. It was developed by Eli Lilly and is marketed under the brand names Tazac and Axid.
Contents
1Clinical use
2Adverse effects
3History and development
4See also
5References
6External links
Clinical use
Main article: H2 antagonist
Nizatidine is used to treat duodenal ulcers, gastric ulcers, and gastroesophageal reflux disease (GERD/GORD), and to prevent stress ulcers.[1]
Adverse effects
Side effects are uncommon, usually minor, and include diarrhea, constipation, fatigue, drowsiness, headache, and muscle aches.[1]
History and development
Nizatidine was developed by Eli Lilly, and was first marketed in 1987. It is considered to be equipotent with ranitidine and differs by the substitution of a thiazole ring in place of the furan ring in ranitidine. In September 2000, Eli Lilly announced they would sell the sales and marketing rights for Axid to Reliant Pharmaceuticals.[2] Subsequently, Reliant developed the oral solution of Axid, marketing this in 2004, after gaining approval from the U.S. Food and Drug Administration (FDA).[3] However, a year later, they sold rights of the Axid Oral Solution (including the issued patent[4] protecting the product) to Braintree Laboratories.[5]
Nizatidine proved to be the last new histamine H2 receptor antagonist introduced prior to the advent of proton pump inhibitors.[citation needed]
See also
Famotidine (Pepcid) — another popular H2 receptor antagonist
5. 早産児における胃食道逆流 gastroesophageal reflux in premature infants
English Journal
Homology Modeling and Antagonist Binding Site Study of the Human Histamine H2 Receptor.
Zhang J, Qi T, Wei J.SourceTianjin Key Laboratory for Modern Drug Delivery & High-Efficiency, School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, P. R. China. betty_wj@tju.edu.cn.
Medicinal chemistry (Shariqah (United Arab Emirates)).Med Chem.2012 Jul 10. [Epub ahead of print]
On the basis of the high resolution crystal structures of bovine rhodopsin, human beta2-adrenergic receptor and human A2a adenosine receptor, three-dimensional structure of the human histamine H2 receptor (HHR2) was developed by homology modeling. Results of the evaluations suggest that a high quali
Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients.
Takahashi N, Miura M, Niioka T, Sawada K.SourceDepartment of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan.
Cancer chemotherapy and pharmacology.Cancer Chemother Pharmacol.2012 Apr;69(4):999-1004. Epub 2011 Dec 7.
PURPOSE: The objective of this study was to investigate the drug interaction between dasatinib and the gastric acid suppressants (H2-receptor antagonists (H2RA) famotidine and nizatidine and the proton pump inhibitor (PPI) lansoprazole in leukemia Japanese patients.METHODS: Eighteen patients treated
Learn about the prescription medication Axid (Nizatidine), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. ... FDA Approves First Generic Versions of Aciphex to treat GERD » "The U.S. Food ...
